Abstracts Archive - Page 2082 of 2607 - ACR Meeting Abstracts

Abstract Number: 2278 • 2014 ACR/ARHP Annual Meeting
Orbital Pseudotumor As the Presenting Symptom of Pediatric ANCA-Associated Vasculitis
Amanda Schlefman¹, Maureen Leffler², AnneMarie C. Brescia³ and Carlos D. Rose⁴, ¹A.I. DuPont Hospital for Children, Wilmington, DE, ²Rheumatology, AI duPont Hospital for Children, Wilmington, DE, ³Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ⁴Pediatrics, Division of Rheumatology, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE
Background/Purpose: Ocular involvement, particularly orbital pseudotumor, has been reported as the initial manifestation of ANCA-associated vasculitis (AAV) in the adult population, predominantly in granulomatosis with…
Abstract Number: 2279 • 2014 ACR/ARHP Annual Meeting
Evidence Based Recommendations for Diagnosis and Management of Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS)
Nienke ter Haar¹, Paul Brogan², Gilles Grateau³, Jordi Anton⁴, Karyl Barron⁵, Luca Cantarini⁶, Joost Frenkel⁷, Caroline Galeotti⁸, Veronique Hentgen⁹, Michael Hofer¹⁰, Tilmann Kallinich¹¹, Isabelle Kone-Paut¹², Jasmin Kuemmerle-Deschner¹³, Huri Ozdogan¹⁴, Seza Ozen¹⁵, Ricardo Russo¹⁶, Anna Simon¹⁷, Yosef Uziel¹⁸, Carine Wouters¹⁹, Brian Feldman²⁰, Bas Vastert⁷, Nico Wulffraat²¹, Helen Lachmann²² and Marco Gattorno²³, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology Unit, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ³Service De Médecine Interne, Hopital Tenon, Paris, France, ⁴Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, ⁵NIH, Bethesda, MD, ⁶University of Siena, Siena, Italy, ⁷University Medical Center Utrecht, Utrecht, Netherlands, ⁸Bicêtre Hospital, University of Paris SUD, Paris, France, ⁹Versailles Hospital, Le Chesnay Cedex, France, ¹⁰Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ¹¹Charite, University Medicine Berlin, Berlin, Germany, ¹²Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, ¹³Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ¹⁴Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ¹⁵Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ¹⁶Immunology & Rheumatology, Hospital De Pediatria, Buenos Aires, Argentina, ¹⁷Radboudumc, Nijmegen, Netherlands, ¹⁸Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ¹⁹University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, ²⁰Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²¹Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²²UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ²³Istituto Giannina Gaslini, Genova, Italy
Background/Purpose Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS) is a rare hereditary autoinflammatory syndrome that can lead to significant morbidity. Evidence-based guidelines are lacking…
Abstract Number: 2280 • 2014 ACR/ARHP Annual Meeting
Evidence Based Recommendations for the Management of Cryopyrin Associated Periodic Syndromes (CAPS)
Nienke ter Haar¹, Marlen Oswald², Luca Cantarini³, Marco Gattorno⁴, Michael Hofer⁵, Isabelle Kone-Paut⁶, Jordi Anton Lopez⁷, Karyl Barron⁸, Paul Brogan⁹, Joost Frenkel¹⁰, Caroline Galeotti¹¹, Gilles Grateau¹², Veronique Hentgen¹³, Tilmann Kallinich¹⁴, Helen Lachmann¹⁵, Huri Ozdogan¹⁶, Seza Ozen¹⁷, Ricardo Russo¹⁸, Anna Simon¹⁹, Yosef Uziel²⁰, Carine Wouters²¹, Brian Feldman²², Bas Vastert¹⁰, Nico Wulffraat²³, Susanne Benseler²⁴ and Jasmin Kuemmerle-Deschner²⁵, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²University Hospital Tuebingen, Tuebingen, Germany, ³University of Siena, Siena, Italy, ⁴Pediatric Rheumatology, Instituto Giannina Gaslini, Genoa, Italy, ⁵Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ⁶Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, ⁷pediatric Rheumatology, University Childrenxs Hospital, Barcelona, Spain, ⁸NIH, Bethesda, MD, ⁹Rheumatology Unit, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ¹⁰University Medical Center Utrecht, Utrecht, Netherlands, ¹¹Bicêtre Hospital, University of Paris SUD, Paris, France, ¹²Service De Médecine Interne, Hopital Tenon, Paris, France, ¹³Versailles Hospital, Le Chesnay Cedex, France, ¹⁴Charite, University Medicine Berlin, Berlin, Germany, ¹⁵UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁶Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ¹⁷Hacettepe University, Ankara, Turkey, ¹⁸Immunology & Rheumatology, Hospital De Pediatria, Buenos Aires, Argentina, ¹⁹Radboudumc, Nijmegen, Netherlands, ²⁰Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ²¹University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, ²²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²³Paediatric Immunology and Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²⁴The Hospital for Sick Children, Toronto, ON, Canada, ²⁵Pediatrics, University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose Cryopyrin-associated periodic syndromes (CAPS) is a group of rare monogenetic autoinflammatory disorders. Evidence-based guidelines are lacking and management is mostly based on physician’s experience. Consequently,…
Abstract Number: 2281 • 2014 ACR/ARHP Annual Meeting
Dissecting the Heterogeneity of Macrophage Activation Syndrome
Francesca Minoia¹, Sergio Davì¹, AnnaCarin Horne², Francesca Bovis³, Erkan Demirkaya⁴, Alessandro Consolaro⁵, Jonathan Akikusa⁶, Nuray Aktay Ayaz⁷, Patrizia Barone⁸, Bianca Bica⁹, Isabel Bolt¹⁰, Luciana Breda¹¹, Zane Davidsone¹², Carmen De Cunto¹³, Jaime De Inocencio¹⁴, Sandra Enciso¹⁵, Romina Gallizzi¹⁶, Thomas Griffin¹⁷, Teresa Hennon¹⁸, Gerd Horneff¹⁹, Maka Ioseliani²⁰, Michael Jeng²¹, Agneza Marija Kapovic²², Bianca Lattanzi⁵, Jeffrey M Lipton²³, Silvia Magni-Manzoni²⁴, Clarissa Nassif²⁵, Ingrida Rumba-Rozenfelde²⁶, Claudia Saad-Magalhães²⁷, Sulaiman Almayouf²⁸, Wafaa Al-Suwairi²⁹, Kimo C Stine³⁰, Olga Vougiouka³¹, Lehn K. Weaver³², Nicolino Ruperto³³, Alberto Martini^5,34, Randy Q. Cron³⁵ and Angelo Ravelli³⁴, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden, ³Pediatria II, PRINTO, PRINTO - Istituto Giannina Gaslini, Genoa, Italy, ⁴Gulhane Military Medical Faculty, Ankara, Turkey, ⁵Istituto Giannina Gaslini, Genova, Italy, ⁶3 West Clinical Offices, Royal, Royal Children's Hospital, Melbourne, Australia, ⁷Bakırkoy Maternity and Childrens Education and Research Hospital, Istanbul, Turkey, ⁸Azienda Policlinico Università di Catania, Catania, Italy, ⁹Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil, ¹⁰Kinderspital Zuerich, Universitaetskinderklinik, Zurich, Switzerland, ¹¹Department of Paediatrics, University of Chieti G. D'Annunzio, Chieti, Italy, ¹²Children's University Hospital, Riga, Latvia, ¹³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁴Hospital 12 de Octubre, Madrid, Spain, ¹⁵Hospital Infantil de Mexico Federico Gomez in Mexico City, Mexico City, Mexico, ¹⁶University of Messina, Messina, Italy, ¹⁷Pediatrics, Division of Rheumatology, Levine Children's Hospital, Carolinas Medical Ctr, Charlotte, NC, ¹⁸Division of Pediatric Allergy/Immunology/Rheumatol, Women & Children's Hospital of Buffalo, Buffalo, NY, ¹⁹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²⁰M. Iashvili Children's Central Clinic, Tbilisi, Georgia, ²¹Stanford University, Stanford, CA, ²²Children's Hospital Zagreb, Zagreb, Croatia, ²³Steven and Alexandra Cohen Children's Hospital of New York, New York, NY, ²⁴Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²⁵Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ²⁶University of Latvia, Riga, Latvia, ²⁷Alameda Das Hortensias 868, Botucatu Medical School, Botucatu, Brazil, ²⁸King Faisal Specialist H.,Riyadh, Riyadh, Saudi Arabia, ²⁹Pediatric, King AbdulAziz Medical City, Riyadh, Saudi Arabia, ³⁰Arkansas Children's Hospital, Little Rock, AR, ³¹P. A. Kyriakou Childrens Hospital of Athens University, Athens, Greece, ³²Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ³³Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ³⁴University of Genova, Genova, Italy, ³⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Macrophage activations syndrome (MAS) occurring in the context of systemic juvenile idiopathic arthritis (sJIA) can pursue a rapidly fatal course. However, the diagnosis of…
Abstract Number: 2282 • 2014 ACR/ARHP Annual Meeting
Evidence Based Recommendatinos for Diagnosis and Management of Mevalonate Kinase Deficiency (MKD)
Nienke ter Haar¹, Jerold Jeyaratnam², Jordi Anton³, Caroline Galeotti⁴, Karyl Barron⁵, Paul Brogan⁶, Luca Cantarini⁷, Marco Gattorno⁸, Gilles Grateau⁹, Veronique Hentgen¹⁰, Michael Hofer¹¹, Tilmann Kallinich¹², Isabelle Kone-Paut¹³, Jasmin Kuemmerle-Deschner¹⁴, Helen Lachmann¹⁵, Huri Ozdogan¹⁶, Seza Ozen¹⁷, Ricardo Russo¹⁸, Yosef Uziel¹⁹, Carine Wouters²⁰, Brian Feldman²¹, Bas Vastert², Nico Wulffraat²², Anna Simon²³ and Joost Frenkel², ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands, ³Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, ⁴Bicêtre Hospital, University of Paris SUD, Paris, France, ⁵NIH, Bethesda, MD, ⁶Rheumatology Unit, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁷University of Siena, Siena, Italy, ⁸Istituto Giannina Gaslini, Genova, Italy, ⁹Service De Médecine Interne, Hopital Tenon, Paris, France, ¹⁰Versailles Hospital, Le Chesnay Cedex, France, ¹¹Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ¹²Charite, University Medicine Berlin, Berlin, Germany, ¹³Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, ¹⁴Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ¹⁵UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁶Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ¹⁷Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ¹⁸Immunology & Rheumatology, Hospital De Pediatria, Buenos Aires, Argentina, ¹⁹Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ²⁰University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, ²¹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²²Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²³Radboudumc, Nijmegen, Netherlands
Background/Purpose Mevalonate kinase deficiency (MKD) is a rare hereditary autoinflammatory syndrome that can lead to significant morbidity. Evidence-based guidelines are lacking and management is mostly…
Abstract Number: 2283 • 2014 ACR/ARHP Annual Meeting
Steroid-Sparing Effect of Anakinra (Kineret^®) in the Treatment of Patients with Severe Cryopyrin-Associated Periodic Syndrome
Bengt Hallén, Mika Leinonen, Torbjörn Kullenberg and Hans Olivecrona, Swedish Orphan Biovitrum, Stockholm, Sweden
Background/Purpose Cryopyrin-Associated Periodic Syndromes (CAPS) include a group of rare inherited autoinflammatory diseases consisting of FCAS, Muckle-Wells Syndrome and the most severe form, NOMID. Reduction…
Abstract Number: 2284 • 2014 ACR/ARHP Annual Meeting
Joint Involvement in Pediatric Crohn’s Disease Is Related to Higher Disease Activity and Worse Quality of Life
Beata Derfalvi^1,2, Gabor Bozsaki³, Doloresz Szabo³, Aron Cseh³, Katalin Eszter Muller³, Andras Arato³ and Gabor Veres³, ¹Pediatrics, Dalhousie University, Halifax, NS, Canada, ²2nd. Dept. of Pediatrics, Semmelweis University, Budapest, Hungary, ³1st. Dept. of Pediatrics, Semmelweis University, Budapest, Hungary
Background/Purpose: The incidence of arthritis and arthralgia in pediatric patients with Crohn's disease (CD) is reported to be 2–15% and 22%, respectively. The aim of our…
Abstract Number: 2285 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Rilonacept in Patients with Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
Dawn C. Chapelle Neal¹, Adriana Almeida de Jesus², Yan Huang³, Yin Liu³, Raphaela Goldbach-Mansky³ and Gina Montealegre⁴, ¹National Institutes of Health, NIAMS/NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section, NIAMS/NIH, Bethesda, MD, ³Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁴Office of the Clinical Director, NIAMS/NIH, Bethesda, MD
Background/Purpose: Deficiency of interleukin-1 receptor antagonist (DIRA) is a neonatal-onset autoinflammatory syndrome caused by recessive mutations in IL1RN gene, the gene encoding the interleukin-1-receptor antagonist.…
Abstract Number: 2286 • 2014 ACR/ARHP Annual Meeting
Food Allergy and Celiac Disease in Children with Juvenile Idiopathic Arthritis
Trevor E. Davis^1,2, Mei-Sing Ong³, Diana Milojevic², Jyoti Ramakrishna⁴ and Marc D. Natter⁵, ¹Medicine, Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Pediatrics, Division of Pediatric Rheumatology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ³Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia, ⁴Pediatrics, Division of Pediatric Gastroenterology and Nutrition, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁵Intelligent Health Labs, Children's Hospital Boston, Boston, MA
Background/Purpose: There are multiple strong associations between gut pathology and rheumatologic diseases. This connection, between primary GI disease and rheumatologic diseases, is manifest in both…
Abstract Number: 2287 • 2014 ACR/ARHP Annual Meeting
Cartilage Thickness and Bone Health in Children with Juvenile Idiopathic Arthritis
Marinka Twilt¹, Dan Pradsgaard², Anne Helene Spannow², Arne Horlyck³, Carsten Heuck² and Troels Herlin⁴, ¹Paediatrics, Aarhus University Hospital, Aarhus, Denmark, ²paediatrics, Aarhus University Hospital, Aarhus, Denmark, ³radiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose Although treatment options have increased and morbidity has decreased in the last decade Juvenile Idiopathic Arthritis (JIA) may still result in disability. Increasingly ultrasonography…
Abstract Number: 2288 • 2014 ACR/ARHP Annual Meeting
The Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Independent Risk Factors and Medication Use in New Onset Uveitis in Juvenile Idiopathic Arthritis
Jennifer JY Lee¹, Ciarán M. Duffy², Jaime Guzman³, Nick Barrowman⁴, Deepti Reddy⁴, Kimberly Morishita⁵, Lynn R. Spiegel⁶, Elizabeth Stringer⁷, Michele Gibbon², Rae S.M. Yeung⁸, Lori B. Tucker³, Kiem Oen⁹, Karen N Watanabe Duffy² and ReACChOut Investigators², ¹Pediatrics, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ²Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ³Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁴Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ⁵BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁶The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁷Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁸Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: The Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh Out) cohort is a multi-centre prospective inception cohort of newly diagnosed Juvenile Idiopathic Arthritis…
Abstract Number: 2289 • 2014 ACR/ARHP Annual Meeting
Accuracy of the Use of Administrative Diagnostic Codes to Identify Pediatric in-Patient Musculoskeletal Conditions in an African Tertiary Hospital
Rosie Scuccimarri¹, Carol Hitchon², Sasha Bernatsky³, Eugene Were⁴, Thomas Ngwiri⁵ and Ines Colmegna⁶, ¹Rheumatology, Montreal Children's Hospital, Montreal, QC, Canada, ²Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴Gertrude's Children's Hospital, Nairobi, Kenya, ⁵Pediatrics, Gertrude's Children's Hospital, Nairobi, Kenya, ⁶Rheumatology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The spectrum and frequency of pediatric rheumatic conditions in East Africa are unknown. Administrative data that is systematically collected using International Classification of Disease…
Abstract Number: 2290 • 2014 ACR/ARHP Annual Meeting
Race and Other Risk Markers of Uveitis in a Prospective Cohort of Children with Juvenile Idiopathic Arthritis
Sheila T. Angeles-Han¹, Courtney McCracken¹, Steven Yeh², Kirsten Jenkins³, Erica Myoung⁴, Daneka Stryker⁴, Kelly A. Rouster-Stevens⁵, Larry B. Vogler¹, Christine Kennedy⁶, Sampath Prahalad¹ and Carolyn Drews-Botsch⁷, ¹Emory University School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory University, Atlanta, GA, ⁵Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Rheumatology Immunology, Emory Children's Center, Atlanta, GA, ⁷Epidemiology, Emory University School of Public Health, Atlanta, GA
Background/Purpose Juvenile idiopathic arthritis-associated uveitis (JIA-U) can lead to poor visual outcomes. American Academy of Pediatric guidelines recommend screening every 3 months in children with…
Abstract Number: 2291 • 2014 ACR/ARHP Annual Meeting
Canakinumab in Biologic-naïve Versus Previously Biologic-Exposed Systemic Juvenile Idiopathic Arthritis Patients: Efficacy Results from a 12 Week Pooled Post Hoc Analysis
A Grom¹, P Quartier², N Ruperto³, H.I Brunner¹, K Schikler¹, M Erguven³, L Goffin³, M Hofer³, T Kallinich³, K Marzan¹, C Gaillez⁴, K Lheritier⁴, K Abrams⁵, A Martini³ and D.J Lovell¹, ¹PRCSG, Cincinnati, OH, ²Hôpital Necker-Enfants Malades, Paris, France, ³PRINTO-Istituto Gaslini, Genova, Italy, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceutical Corporation, East Hanover, NJ
Background/Purpose: Efficacy and safety of canakinumab (CAN), a selective, human, anti-IL-1β monoclonal antibody, was previously demonstrated in 2 phase III trials.1 Out of these trials…
Abstract Number: 2251 • 2014 ACR/ARHP Annual Meeting
Kneeling Disability Associated with the Treatment of Osteoarthritis: Analysis of a Copcord Study in Mexico
Alexia Hernández-Cáceres¹, Jacqueline Rodríguez-Amado¹, Ingris Peláez-Ballestas², David Vega-Morales³, Mario Garza-Elizondo¹, Roberto Negrete-López¹, Lorena Pérez-Barbosa¹ and Janett Riega-Torres¹, ¹Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Departamento de Reumatología, Departamento de Reumatología Hospital General de México “Dr. Eduardo Liceaga”, Distrito Federal, Mexico, ³Rheumatology, Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose Osteoarthritis (OA) is the most prevalent rheumatic disease in Mexico. The core treatment, a combination of pharmacological and non-pharmacological modalities, is mainly performed in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].